Flashcards · Module 41
💊 Deprescribing Frameworks & Specific Tapering Protocols
4 of 4 cards published · read by the site’s author on 22 November 2026
PPI Deprescribing Algorithm: Escaping the rebound acid trap
Needs clinical review
The Overuse Epidemic:
In one cohort of hospitalised older adults, 62.4% of those on drugs for ulcer or reflux were inappropriately treated (often started as stress ulcer prophylaxis in hospital and never stopped!).
Possible Harms of Long-Term PPIs (small, but higher in older people):
🦠 Infections: C. difficile colitis (pooled risk 1.69), hospital-acquired pneumonia.
🦴 Fractures: Inhibits calcium and magnesium absorption → accelerated osteoporosis and hip fractures.
🧪 Nutritional Deficits: Vitamin B12 malabsorption, hypomagnesemia.
🫘 Renal: Acute interstitial nephritis (AIN) and chronic kidney disease.
The Rebound Acid Hypersecretion Trap:
Stopping a PPI abruptly can cause rebound acid hypersecretion from a compensatory rise in acid production. The patient experiences burning reflux and assumes they "need the pill forever."
How to Deprescribe (Canadian guideline):
Lower the daily dose, or stop and use it on demand, once symptoms have resolved after at least 4 weeks of treatment.
Or switch to an H2-receptor antagonist (a weaker suggestion).
Not for Barrett's oesophagus, severe (grade C or D) oesophagitis or a past bleeding ulcer.
Sources checked (11) · 21 November 2026
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline (2017)
- Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly (2011)
- Overutilization of proton-pump inhibitors: what the clinician needs to know (2012)
- Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis (2012)
- Acid-suppressive medications and risk of pneumonia in acute stroke patients: A systematic review and meta-analysis (2019)
- Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications (2013)
- Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis (2020)
- Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency (2013)
- Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies (2015)
- Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease (2016)
- Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive? (2024)
Note: The Canadian guideline notes that rebound symptoms are hard to tell from returning reflux, and that their clinical significance is unknown. (Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline (2017))
Antihypertensive Deprescribing in Frailty & Low DBP
Needs clinical review
The J-Curve Phenomenon in Geriatric Blood Pressure:
Lower is NOT always better in frail older adults!
Why Low Diastolic Blood Pressure (DBP) is Deadly:
Coronary arteries fill predominantly during diastole!
In older adults with stiff, calcified aorta, wide pulse pressure is common (e.g., BP 150/55).
Lowering systolic BP aggressively can push diastolic BP to levels that may compromise myocardial perfusion.
Diastolic BP below 60 mmHg has been linked to subclinical myocardial damage, coronary events and death (observational data).
In SPRINT's oldest participants, intensive control brought slightly more hypotension (2.4% vs 1.4%) and syncope (3.0% vs 2.4%), differences that were not statistically significant.
When to Deprescribe Antihypertensives:
Low systolic BP (below 130 mmHg in the PARTAGE nursing-home study) while on two or more BP drugs, in a frail patient.
Diastolic BP < 60 mmHg.
Significant symptomatic orthostatic hypotension (SBP drop ≥20 mmHg).
SPRINT-Senior showed tight control helps fit elders, but multimorbid nursing home residents were excluded from those trials.
Sources checked (6) · 21 November 2026
- Antihypertensive medication in frail older adults: A narrative review through a deprescribing lens (2022)
- Treatment With Multiple Blood Pressure Medications, Achieved Blood Pressure, and Mortality in Older Nursing Home Residents: The PARTAGE Study (2015)
- Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control (2016)
- Regulation of coronary blood flow during exercise (2008)
- Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial (2016)
- Relationship between sarcopenia and orthostatic hypotension (2020)
Antipsychotic Tapering in Dementia: Escaping the chemical restraint
Needs clinical review
The CMS Mandate:
US nursing home rules (CMS) call for gradual dose reduction (GDR) or discontinuation of antipsychotics.
When Can You Safely Deprescribe?
If an older adult with dementia was started on an antipsychotic (e.g., Risperidone, Quetiapine) for agitation or psychosis, attempt deprescribing after at least 3 months of treatment (symptoms stable, or no response).
The Tapering Protocol:
Taper slowly: e.g., reduce the dose by 25% to 50% every 1 to 2 weeks (clinicians piloting the guideline preferred slower).
Prefer a slow taper to stopping abruptly.
Watch for symptoms returning: in most trials, outcomes did not differ between stopping and continuing.
The Evidence:
Clinical trials (like the DART-AD study) show that deprescribing antipsychotics in dementia does not, on average, worsen behavioural symptoms, with no consistent change in cognition in most patients!
Sources checked (5) · 21 November 2026
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline (2018)
- Improving Nursing Home Compliance via Revised Antipsychotic Use Survey Tool (2017)
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline (2018)
- Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia (2013)
- A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) (2008)
Benzodiazepine & Z-Drug Slow Tapers: The Ashton Protocol
Needs clinical review
Why Benzodiazepines Are Risky in Older Adults:
Benzos (Lorazepam, Alprazolam) and Z-drugs (Zolpidem) cause:
Increased hip fracture risk (RR 1.34 in one meta-analysis) and falls
60% to 80% increased traffic accident risk (OR 1.59–1.81)
Cognitive problems
Physical dependence
The Ashton Tapering Strategy:
Switching to a long half-life agent (diazepam) is optional: it has not been shown to reduce withdrawal symptoms or improve success more than tapering the original drug.
The "Turtle Taper": reduce by about 25% every 2 weeks, slowing to 12.5% steps near the end, then planned drug-free days.
Behavioral Support: add CBT for insomnia: it improves stopping rates over tapering alone, though the gain fades in the long term.
Sources checked (5) · 21 November 2026
- The treatment of benzodiazepine dependence (1994)
- Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline (2018)
- Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline (2018)
- Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies (2020)
- Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence (2011)
Note: Ashton's approach uses diazepam for convenience of dosage strengths, but tapering can be done directly from the original drug. (The treatment of benzodiazepine dependence (1994))